IP Library Patent Application 11826381
Patent Application
App. No. 11/826,381

Microencapsulated 3-piperidinyl-substituted 1,2-benzisoxazoles and 1,2-benzisothiazoles

Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US None
App. No.
11/826,381
Abstract

Sustained-release microparticle composition. The microparticle composition can be formulated to provide extended release and a duration of action of from about 7 days to about 200 days. The microparticles may be formulated with a biodegradable and biocompatible polymer, and an active agent, such as risperidone, 9-hydroxy-risperidone, and pharmaceutically acceptable acid addition salts of the foregoing.

Claims (2)

1 . A formulation, comprising:

sustained-release microparticles comprising a biodegradable and biocompatible polymer and an active agent selected from the group consisting of risperidone, 9-hydroxy-risperidone, and pharmaceutically acceptable acid addition salts of the foregoing, wherein the formulation has a duration of action for the treatment of psychotic disorders from about 7 days to about 200 days.

Assignments (4)
MERGER Recorded Feb 10, 2009
From: ALKERMES CONTROLLED THERAPEUTICS INC. II
To: ALKERMES, INC.
Reel/Frame 022236/0503 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 6, 2009
From: MEDISORB TECHNOLOGIES INTERNATIONAL, L.P.
To: ALKERMES CONTROLLED THERAPEUTICS, INC. II
Reel/Frame 022214/0615 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 4, 2009
From: MESENS, JEAN
To: JANSSEN PHARMACEUTICA
Reel/Frame 022203/0575 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 26, 2009
From: RICKEY, MICHAEL E.; ATKINS, THOMAS J.
To: MEDISORB TECHNOLOGIES INTERNATIONAL, L.P.
Reel/Frame 022151/0421 →